文献速递角膜与眼表疾病青光眼

既往青光眼手术后DMEK四年移植物存活情况

Four-Year Survival of Descemet Membrane Endothelial Keratoplasty in Patients With Previous Glaucoma Surgery.
PubMed 文献 · Am J Ophthalmol · 2020-05-22

本回顾性对比病例系列纳入既往接受小梁切除术或青光眼引流装置植入后行DMEK的患眼,并与Fuchs角膜内皮营养不良DMEK患眼按随访时长匹配。研究组4年移植物存活概率显著低于对照组,排斥率和内皮细胞丢失更高。

要点

  • 既往青光眼手术后DMEK早期结果良好,但长期排斥与失败率高。
  • 研究组48个月移植物存活概率为27%,对照组为88%。
  • 研究组排斥率为19.6%,对照组为2.3%。

核心结论

  • 既往青光眼手术后行DMEK的患眼早期结果良好,但长期排斥率和失败率较高,医生和患者应认识到该情形下移植物失败可能性高。

研究设计与样本

  • 回顾性、对比性病例系列。
  • 研究组为既往小梁切除术或青光眼引流装置植入后行DMEK的患眼,对照组为Fuchs角膜内皮营养不良DMEK患眼,按随访时长匹配。
  • 研究组为49例患者的51只眼(GDD 32只眼,无GDD 19只眼),对照组为42例患者的43只眼。
  • 研究组和对照组平均随访分别为37.9±15.2个月和33.8±13.5个月(P = .322)。

主要发现

  • 研究组12、24、36、48个月移植物存活概率分别为75%、60%、43%、27%,对照组为持续的88%(P < .001)。
  • GDD和无GDD两个亚组的存活曲线均显著低于对照组(P < .001)。
  • 研究组和对照组排斥率分别为19.6%和2.3%(P = .010)。
  • 研究组内皮细胞丢失在12、24、36、48个月比对照组高12%-22%(P = .049、P = .027、P = .200、P = .004)。

关键数值与推荐

  • 主要结局为移植物存活率和排斥率,次要结局包括脱离/再次气泡发生率、内皮细胞丢失、最佳矫正视力、眼压及青光眼药物/手术情况。
  • 亚组分析比较有和无GDD的患眼。

临床怎么用

  • 对既往接受青光眼手术的患者行DMEK前,应告知其长期移植物失败和排斥风险较高。
  • 术后需加强长期随访与排斥监测,尤其关注GDD患眼。

局限性

  • 为回顾性、对比性病例系列设计。
  • 研究组与对照组平均随访时长存在差异且样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate 4-year outcomes of Descemet membrane endothelial keratoplasty (DMEK) in eyes with previous glaucoma surgery. DESIGN: Retrospective, comparative case series. METHODS: Patients with previous trabeculectomy or glaucoma drainage device (GDD) implantation who later underwent DMEK (study group) were matched for follow-up duration with Fuchs dystrophy DMEK patients (control group). The minimum follow-up was 18 months. Primary outcomes included graft survival and rejection rates, and secondary outcomes included rates of detachment/rebubble, endothelial cell loss, best spectacle-corrected visual acuity, intraocular pressure, and glaucoma medications/surgeries. Subgroup analysis compared eyes with and without a GDD. RESULTS: Ninety-four eyes of 91 patients were included. There were 51 eyes of 49 patients in the study group (GDD = 32 eyes, no GDD = 19 eyes) and 43 eyes of 42 patients in the control group. The mean follow-up was 37.9 ± 15.2 and 33.8 ± 13.5 months, respectively (P = .322). Graft survival probability of the study group at 12, 24, 36, and 48 months was 75%, 60%, 43%, and 27%, respectively, compared with a consistent 88% in the control group (P < .001). Survival curves of study subgroups (GDD and no GDD) were significantly lower than the control group (P < .001). Rejection rates in the study and control groups were 19.6% and 2.3%, respectively (P = .010). Endothelial cell loss in the study group was 12%-22% higher than the control group at 12, 24, 36, and 48 months (P = .049, P = .027, P = .200, and P = .004). CONCLUSIONS: In eyes with previous glaucoma surgery, DMEK has good early outcomes, but longer-term rejection and failure rates are high. Physicians and patients should be cognizant of the high likelihood of graft failure in this setting.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sorkin N, Mimouni M, Kisilevsky E, et al. Four-Year Survival of Descemet Membrane Endothelial Keratoplasty in Patients With Previous Glaucoma Surgery. Am J Ophthalmol. 2020. PMID: 32446739. doi:10.1016/j.ajo.2020.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。